Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.57 |
| ▸ | FAAH | O00519 | 4/20 | 0.51 |
| ▸ | GHSR | Q92847 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15478536 | 1.00 | MTNR1A (0.57) | MTNR1AMTNR1BFAAHGHSRPLAU | |
| SCHEMBL22785039 | 0.90 | MTNR1A (0.53) | MTNR1AMTNR1BFAAHGHSRPLAU | |
| SCHEMBL434294 | 0.86 | MTNR1A (0.47) | MTNR1AMTNR1BFAAHP2RX7 | |
| SCHEMBL6427539 | 0.82 | FAAH (0.53) | MTNR1AMTNR1BFAAHGHSRPLAU | |
| SCHEMBL6534185 | 0.82 | FAAH (0.53) | MTNR1AMTNR1BFAAHGHSRPLAU | |
| SCHEMBL367535 | 0.82 | FAAH (0.53) | MTNR1AMTNR1BFAAHGHSRPLAU | |
| SCHEMBL5608206 | 0.82 | FAAH (0.53) | MTNR1AMTNR1BFAAHGHSRPLAU | |
| SCHEMBL1193346 | 0.82 | FAAH (0.53) | MTNR1AMTNR1BFAAHGHSRPLAU | |
| SCHEMBL11790481 | 0.81 | MTNR1A (0.54) | MTNR1AMTNR1BFAAHGHSRPLAU | |
| SCHEMBL346421 | 0.81 | PLAU (0.52) | MTNR1AMTNR1BFAAHGHSRPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345917-B1 | ANTIPROTOZOAL COMPOUNDS | BACOBA AG (CH) | 2021-11-17 | — | — | EP | disclosed |
| US-11174282-B2 | Aminosteroid derivatives and process for producing same | UNIVERSITé LAVAL (CA) | 2021-11-16 | — | — | US | disclosed |
| EP-3345917-A1 | ANTIPROTOZOAL COMPOUNDS | Bacoba AG (CH) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017217553-A1 | OXIME COMPOUND AND HERBICIDE | 日産化学工業株式会社 | 2017-12-21 | — | — | WO | disclosed |
| WO-2017205964-A1 | AMINOSTEROID DERIVATIVES AND PROCESS FOR PRODUCING SAME | UNIVERSITé LAVAL (CA) | 2017-12-07 | — | — | WO | disclosed |
| US-9630923-B2 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | EUTICALS SPA (IT) | 2017-04-25 | — | — | US | disclosed |
| US-20160122303-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | AMRI ITALY S.R.L. (IT) | 2016-05-05 | — | — | US | disclosed |
| EP-2153832-B1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2285787-B1 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-08-26 | — | — | EP | disclosed |
| US-20140179845-A1 | SUBSTITUTED NAPHTHALENES AS FEEDSTOCK FOR PLASTICIZER PRODUCTION | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2014-06-26 | — | — | US | disclosed |
| US-5552444-A | AGONIST ACTIVITY AT SEROTONIN RECEPTORS, ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| US-5470977-A | Serotonin 1A receptor agonists | ELI LILLY AND COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| US-5466709-A | Serotonin receptors | ELI LILLY AND COMPANY (US) | 1995-11-14 | — | — | US | disclosed |
| US-5426229-A | Treatment of sleep, sex, memory and appetite disorders depression, and anxiety; serotinin inhibitors | ELI LILLY AND COMPANY (US) | 1995-06-20 | — | — | US | disclosed |
| US-5286753-A | Serotonin 1a receptor agonists | ELI LILLY AND COMPANY (US) | 1994-02-15 | — | — | US | disclosed |
| EP-0310745-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | ORION-YHTYMÄ OY (FI) | 1993-01-27 | — | — | EP | disclosed |
| EP-0183492-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos-Yhtyma Oy (FI) | 1989-11-15 | — | — | EP | disclosed |
| EP-0310745-A2 | Substituted imidazole derivatives and their preparation and use | ORION-YHTYMÄ OY (FI) | 1989-04-12 | — | — | EP | disclosed |
| US-4689339-A | 4-dihydroinden-2-yl-, 4-tetrahydronaphth-2-yl-, and 4-dihydrobenzofuran-2-ylimidazoles, useful to block α2 -adrenergic receptors | FARMOS YHTYMA OY (FI) | 1987-08-25 | — | — | US | disclosed |
| EP-0183492-A1 | Substituted imidazole derivatives and their preparation and use | Farmos-Yhtyma Oy (FI) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122303-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | CYP2S1, PRMT3, ARGLU1 | MTNR1A 1216/4885MTNR1B 423/4885FAAH 2518/4885 |
| US-20140179845-A1 | SUBSTITUTED NAPHTHALENES AS FEEDSTOCK FOR PLASTICIZER PRODUCTION | OXER1, RER1, ACOX1 | MTNR1A 1472/4885MTNR1B 2673/4885FAAH 638/4885 |
| US-11174282-B2 | Aminosteroid derivatives and process for producing same | HSD17B11, HSD17B7, CYP19A1 | MTNR1A 2684/4885MTNR1B 2181/4885FAAH 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.